

LISTING OF THE CLAIMS

1-179. (Canceled)

180. (Previously Presented) An isolated polypeptide consisting of a sequence as set forth as SEQ ID NO: 55 or a fragment thereof that is at least 8 amino acids in length.

181. (Previously Presented) The isolated polypeptide of claim 180, wherein the fragment is at least 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 75 or 100 amino acids in length.

182. (Previously Presented) A composition comprising the isolated polypeptide of claim 180 or 181 and a pharmaceutically acceptable carrier.

183. (Previously Presented) The composition of claim 182, wherein the composition further comprises an adjuvant.

184. (Previously Presented) The composition of claim 182, wherein the composition further comprises a cytokine.

185. (Previously Presented) The composition of claim 182, wherein the composition further comprises a costimulatory molecule.

186. (Previously Presented) The composition of claim 182, wherein the composition further comprises a MHC molecule, and wherein the isolated polypeptide is complexed to the MHC molecule.

187. (Previously Presented) The composition of claim 186, wherein the MHC molecule is a HLA class I molecule.

188. (Previously Presented) The composition of claim 186, wherein the MHC molecule is a HLA class II molecule.

189. (Previously Presented) A kit for detecting antibodies reactive to a sarcoma-associated antigen in a biological sample, comprising:

one or more sarcoma-associated antigens consisting of a sequence as set forth as SEQ ID NO: 55 or a fragment thereof that is at least 8 amino acids in length, and

instructions for the use of the sarcoma-associated antigens in the detection of antibodies in the biological sample.

190. (Previously Presented) The kit of claim 189, wherein the fragment is at least 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 75 or 100 amino acids in length.

191. (Previously Presented) The kit of claim 189 or 190, wherein the sarcoma-associated antigen is bound to a substrate.

192. (Previously Presented) An isolated polypeptide comprising a sequence as set forth as SEQ ID NO: 55 or a fragment thereof that is at least 45 amino acids in length.

193. (Previously Presented) The isolated polypeptide of claim 192, wherein the fragment is at least 50, 75 or 100 amino acids in length.

194. (Previously Presented) A composition comprising the isolated polypeptide of claim 192 or 193 and a pharmaceutically acceptable carrier.

195. (Previously Presented) The composition of claim 194, further comprising an adjuvant, a cytokine or a costimulatory molecule.

196. (Previously Presented) The composition of claim 194, wherein the composition further comprises a MHC molecule, and wherein the isolated polypeptide is complexed to the MHC molecule.

197. (Previously Presented) The composition of claim 196, wherein the MHC molecule is a HLA class II molecule.

198. (Previously Presented) A kit for detecting antibodies reactive to a sarcoma-associated antigen in a biological sample, comprising:

one or more sarcoma-associated antigens comprising a sequence as set forth as SEQ ID NO: 55 or a fragment thereof that is at least 45 amino acids in length, and

instructions for the use of the sarcoma-associated antigens in the detection of antibodies in the biological sample.

199. (Previously Presented) The kit of claim 198, wherein the fragment is at least 50, 75 or 100 amino acids in length.

200. (Previously Presented) The kit of claim 198 or 199, wherein the sarcoma-associated antigen is bound to substrate.

201. (Previously Presented) A composition comprising an isolated polypeptide comprising (a) a sequence as set forth as SEQ ID NO: 55 or a fragment thereof that is at least 8 amino acids in length, (b) a MHC molecule and (c) a pharmaceutically acceptable carrier, wherein the isolated polypeptide is complexed to the MHC molecule.

202. (Previously Presented) The composition of claim 201, wherein the fragment is at least 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 75 or 100 amino acids in length.

203. (Previously Presented) The composition of claim 201 or 202, wherein the MHC molecule is a HLA class I molecule.

204. (Previously Presented) The composition of claim 201 or 202, wherein the MHC molecule is a HLA class II molecule.

205. (Previously Presented) A composition comprising an isolated polypeptide comprising (a) a sequence as set forth as SEQ ID NO: 55 or a fragment thereof that is at least 8 amino acids in length, (b) an adjuvant, cytokine, or a costimulatory molecule, and (c) a pharmaceutically acceptable carrier.

206. (Previously Presented) The composition of claim 205, wherein the fragment is at least 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 75 or 100 amino acids in length.